

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: T. Kolasa, et al.

Serial No.: (not yet assigned)

Filed: February 5, 2004

For: OXIMES AND HYDRAZONES THAT
ARE USEFUL IN TREATING SEXUAL
DYSFUNCTION

Attorney Docket No.: 7283.US.01

Examiner: (not yet assigned)

Group Art Unit: (not yet assigned)

EXPRESS MAIL NO.: EV 314261260US

Certificate of Mailing under 37 CFR §1.10:

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service as Express Mail Post Office to Addressee Service with sufficient postage in an envelope addressed as follows:

MS Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Date of Deposit:

2-5-2004

Keri Hermann
~~Kimberly A. Lorio~~ Keri Hermann

INFORMATION DISCLOSURE STATEMENT

MS Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


The following information is submitted, pursuant to 37 CFR §§1.97-1.98 in accordance with Applicant's duty of disclosure under 37 CFR §1.56. This submission is not intended to constitute an admission that any patent, publication or other information cited herein is "prior art" as to the invention claimed. In accordance with 37 CFR §§1.97(g)-(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that other material information as defined by 37 CFR §1.56(a) exists.

Applicants submit herewith Form PTO-1449 listing the references known to them. Applicants respectfully request that the Examiner (1) initial each reference listed on the enclosed Form PTO-1449 indicating that the Examiner has considered and made those references of record in this application and (2) return a copy of the initialed Form PTO-1449 to Applicants. Copies of the references are also enclosed.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits under 37 CFR §1.97(b). Accordingly, no charge is required.

Respectfully submitted,
T. Kolasa, et al.

ABBOTT LABORATORIES
Customer No.: 23492
Telephone: (847) 935-4314
Facsimile: (847) 938-2623



Gabriella Ferrari-Dileo
Registration No. P55,174
Attorney for Applicants

Form PTO - 1449 (Modified)FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.

7283.US.01

SERIAL NO.

Not assigned yet

APPLICANT(S)

T. Kolasa, et al.

FILING DATE

February 5, 2004

GROUP

Not assigned yet

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
B1	1,384,523	02/19/75	Great Britain			
B2	1,378,080	12/18/74	Great Britain			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Andersson, K. et al., "Physiology of penile erection," <i>Physiol. Rev.</i> 75:191-236 (1995)
C2	Hrib, N., "The dopamine D4 receptor: a controversial therapeutic target", <i>Drugs of the Future</i> : 25:587-611 (2000)
C3	DeGroat, W. et al., "Neural Control of Penile Erection, in : Nervous control of urogenital system," <i>Hardwood Academic Publishers, Chur, Switzerland, Vol. 3 (ed. Maggi, C.):467-524 (1993)</i>
C4	Dula, E. et al., "Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction," <i>Urology</i> 56:130-135 (2000)
C5	Milligan, G. et al., "Chimaeric G proteins: their potential use in drug discovery," <i>Trends Pharmacol Sci</i> 20:118-124 (1998)
C6	Missale, C. et al. "Dopamine receptors: from structure to function," <i>Physiol Rev</i> 78:189-225 (1998)
C7	Morales, A. et al., "Oral and Topical Treatment of Erectile Dysfunction: present and future," <i>Urologic Clinics of North America</i> , vol. 22:879-886 (1995)
C8	Moreland, RB, et al., "Prospectives for Pharmacotherapy of Male Erectile Dysfunction," <i>Curr Opinion CPNS Invest Drugs</i> , 2:283-302 (2000)
C9	Padma-Nathan, H. et al., "Efficacy and safety of apomorphine SL vs. placebo for male erectile dysfunction," <i>Urology</i> 161:214 (abstract 821) (1999)
C10	Primus, R. et al., "Localization and characterization of dopamine D ₄ binding sites in rat and human brain by use of the novel D ₄ receptor-selective ligand [³ H]NGD 94-1," <i>J. Pharmacol Exp. Ther</i> 282:1020-1027 (1997)
C11	Melis M., et al., "Dopamine and sexual behavior", <i>Neuroscience and Behavioral Reviews</i> 19: 19-38 (1995)
C12	Suzuki, M. et al., "D ₃ dopamine receptor mRNA is widely express in human brain," <i>Brian Res</i> 779:58-74 (1998)
C13	Vallone, D. et al., "Structure and function of dopamine receptors," <i>Neurosci Biobehav. Rev.</i> 24:125-132 (2000)
C14	Chen F., et al., "Effects of dopamine, apomorphine, gamma hydroxybutiruc acid, haloperidol, and pimozide on reflex bradycardia in rats", <i>J. Pharmacol. Exp. Therap.</i> 214:427-432 (1980)
C15	Hahn R.A. et al., "Primate cardiovascular responses mediated by dopaminergic receptors: effects of N,N-dihydrodopamine and LY171555" <i>J. Pharmacol Exp. Therap.</i> 229:132-138 (1984)
C16	Bendele et al., "Anti-inflammatory activity of pergolide, a dopamine receptor agonist", <i>J. Pharmacol Exp. Therap.</i> 259:169-175 (1991)
C17	Lisconi et al., "Efficacy of bromocriptine in the treatment of metastatic breast cancer and prostate cancer-related hyperprolactinemia", <i>Neuroendocrinology Letters</i> 21:405-408 (2000)
C18	Martinez-Esparza et al., "New 1-Aryl-3-(4-arylpiperazin-1-yl)propane derivatives with dual action at 5-HT _{1A} Serotonin Receptors and Serotonin transporter, as a new class of antidepressant" <i>J. Med. Chem.</i> 44:418-428 (2001)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.

7283.US.01

SERIAL NO.

Not assigned yet

APPLICANT(S)

T. Kolasa, et al.

FILING DATE

February 5, 2004

GROUP

Not assigned yet

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
B1	1,384,523	02/19/75	Great Britain			
B2	1,378,080	12/18/74	Great Britain			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Andersson, K. et al., "Physiology of penile erection," <i>Physiol. Rev.</i> 75:191-236 (1995)
C2	Hrib, N., "The dopamine D4 receptor: a controversial therapeutic target", <i>Drugs of the Future</i> : 25:587-611 (2000)
C3	DeGroat, W. et al., "Neural Control of Penile Erection, in : Nervous control of urogenital system," <i>Hardwood Academic Publishers, Chur, Switzerland, Vol. 3 (ed. Maggi, C.):467-524 (1993)</i>
C4	Dula, E. et al., "Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction," <i>Urology</i> 56:130-135 (2000)
C5	Milligan, G. et al., "Chimaeric G proteins: their potential use in drug discovery," <i>Trends Pharmacol Sci</i> 20:118-124 (1998)
C6	Missale, C. et al. "Dopamine receptors: from structure to function," <i>Physiol Rev</i> 78:189-225 (1998)
C7	Morales, A. et al., "Oral and Topical Treatment of Erectile Dysfunction: present and future," <i>Urologic Clinics of North America</i> , vol. 22:879-886 (1995)
C8	Moreland, RB, et al., "Prospectives for Pharmacotherapy of Male Erectile Dysfunction," <i>Curr Opinion CPNS Invest Drugs</i> , 2:283-302 (2000)
C9	Padma-Nathan, H. et al., "Efficacy and safety of apomorphine SL vs. placebo for male erectile dysfunction," <i>Urology</i> 161:214 (abstract 821) (1999)
C10	Primus, R. et al., "Localization and characterization of dopamine D ₄ binding sites in rat and human brain by use of the novel D ₄ receptor-selective ligand [³ H]NGD 94-1," <i>J. Pharmacol Exp. Ther</i> 282:1020-1027 (1997)
C11	Melis M., et al., "Dopamine and sexual behavior", <i>Neuroscience and Behavioral Reviews</i> 19: 19-38 (1995)
C12	Suzuki, M. et al., "D ₃ dopamine receptor mRNA is widely express in human brain," <i>Brian Res</i> 779:58-74 (1998)
C13	Vallone, D. et al., "Structure and function of dopamine receptors," <i>Neurosci Biobehav. Rev.</i> 24:125-132 (2000)
C14	Chen F., et al., "Effects of dopamine, apomorphine, gamma hydroxybutiruc acid, haloperidol, and pimozide on reflex bradycardia in rats", <i>J. Pharmacol. Exp. Therap.</i> 214:427-432 (1980)
C15	Hahn R.A. et al., "Primate cardiovascular responses mediated by dopaminergic receptors: effects of N,N-dihydrodopamine and LY171555" <i>J. Pharmacol Exp. Therap.</i> 229:132-138 (1984)
C16	Bendele et al., "Anti-inflammatory activity of pergolide, a dopamine receptor agonist", <i>J. Pharmacol Exp. Therap.</i> 259:169-175 (1991)
C17	Lissoni et al., "Efficacy of bromocriptine in the treatment of metastatic breast cancer and prostate cancer-related hyperprolactinemia", <i>Neuroendocrinology Letters</i> 21:405-408 (2000)
C18	Martinez-Esparza et al., "New 1-Aryl-3-(4-arylpiperazin-1-yl)propane derivatives with dual action at 5-HT _{1A} Serotonin Receptors and Serotonin transporter, as a new class of antidepressant" <i>J. Med. Chem.</i> 44:418-428 (2001)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)